Sistema de Información Esencial en Terapéutica y Salud


Última actualización: 21/3/2019
SIETES contiene 92697 citas

<< anterior 21 a 40 de 494 siguiente >>
Presentar resultados
Seleccionar todas
21. Cita con resumen
Alpern JD, Song J, Stauffer WM. Essential medicines in the United States - Why access is diminishing. N Engl J Med 2016;374:1904-7. [Ref.ID 100324]
23.Enlace a cita original Cita con resumen
Laporte JR. Fifty years of pharmacovigilance - Medicines safety and public health. Pharmacoepidemiol Drug Saf 2016;25:725-32. [Ref.ID 99974]
25. Cita con resumen
Stafford N. German drug industry says pricing law is restricting access to some drugs. BMJ 2015;351:h6205. [Ref.ID 99692]
26. Cita con resumen
Naci H, Carter AW, Mossialos E. Why the drug development pipeline is not delivering better medicines. BMJ 2015;351:h5542. [Ref.ID 99639]
27. Cita con resumen
Watson R. Council of Europe tackles drug industry’s “less noble” side. BMJ 2015;351:h5474. [Ref.ID 99593]
28. Cita con resumen
McCarthy M. Law makers question science behind US dietary guidelines. BMJ 2015;351:h5414. [Ref.ID 99592]
29. Cita con resumen
Allen K, Pearson-Stuttard J, Hooton W, Diggle P, Capewell S, O’Flaherty M. Potential of trans fats policies to reduce socioeconomic inequalities in mortality from coronary heart disease in England: cost effectiveness modelling study. BMJ 2015;351:h4583. [Ref.ID 99541]
Milloy M-J, Wood E. Withdrawal from methadone in US prisons: cruel and unusual?. Lancet 2015;386:316-8. [Ref.ID 99366]
31. Cita con resumen
Maynard A, Bloor K. Regulation of the pharmaceutical industry: promoting health or protecting wealth?. J R Soc Med 2015;108:220-2. [Ref.ID 99099]
32. Cita con resumen
Anónimo. Traité commercial États-Unis-Union européenee: menaces sur la santé. Prescrire 2015;35:218-9. [Ref.ID 98927]
33. Cita con resumen
Hortal Carmona J, Aguilar Cruz I, Parrilla Ruiz F. Un modelo de deprescripción. Med Clin (Barc) 2015;144:362-9. [Ref.ID 98879]
34. Cita con resumen
Watson R. Medicines to remain with European Commission Health Directorate. BMJ 2014;349:g6514. [Ref.ID 98359]
35. Cita con resumen
Midzuaray Midzuaray A. Uso racional de medicamentos. Panorama internacional. Revista Salud y Medicamentos 2014;17:21-9. [Ref.ID 98274]
36. Cita con resumen
Watson R. Critics attack transfer of responsibility for drugs in Europe. BMJ 2014;349:g5700. [Ref.ID 98051]
38. Cita con resumen
Martín Matas M. La factura farmacèutica. Ara 2014:42-3. [Ref.ID 97909]
39. Cita con resumen
Frank C, Himmelstein DU, Woolhandler S, Bor DH, Wolfe SM, Heymann O, Zallman L, Lasser KE. Era of faster FDA drug approval has also seen increased black-box warnings and market withdrawals. Health Affairs 2014;33:1453-9. [Ref.ID 97861]
40. Cita con resumen
Anónimo. House democrats want company to justify high cost of hepatitis C treatment. DIA Daily 2014:20 de junio. [Ref.ID 97710]
Seleccionar todas
<< anterior 21 a 40 de 494 siguiente >>